108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
晚期肺癌炎症指数（ALI）对复发或转移性鼻咽癌免疫治疗结局的预后影响：一项多中心事后分析
Authors Xu S, Liu Z, Song G, Pei Y, He M, Ge J, Qing Y, Wei Y, Shao M
Received 15 June 2025
Accepted for publication 20 September 2025
Published 8 October 2025 Volume 2025:18 Pages 13999—14009
DOI https://doi.org/10.2147/JIR.S546584
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tara Strutt
Shihong Xu,1,* Zheran Liu,1,* Ge Song,1,* Yiyan Pei,1 Murong He,2 Junyou Ge,3 Yan Qing,3 Youneng Wei,3 Meiying Shao4
1Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Shenzhen Middle School, Shenzhen, People’s Republic of China; 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, People’s Republic of China; 4West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Meiying Shao, West China School of Public Health and West China Fourth Hospital, Sichuan University, 18#, 3rd Section, Renmin South Road, Chengdu, Sichuan, 610041, People’s Republic of China, Tel +86 028 85508286, Fax +86-28-85423278, Email shaomeiying@scu.edu.cn
Purpose: The Advanced Lung Cancer Inflammation Index (ALI) is a newly introduced index that integrates inflammatory and nutritional statuses to assess malignancies. This study investigates the association between pre-immunotherapy ALI levels and clinical outcomes in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) patients receiving immune checkpoint inhibitors (ICIs) therapy.
Patients and Methods: We conducted an exploratory post hoc analysis of a multicenter, single-arm Phase 2 trial enrolling 153 patients with R/M NPC. This study evaluated the prognostic utility of the pretreatment ALI for overall survival (OS) and progression-free survival (PFS), along with its association with treatment response to ICIs. The optimal ALI cutoff was empirically derived from this cohort. Propensity score matching (PSM) was also applied to assess the independent association between pretreatment ALI and clinical outcomes.
Results: Patients with low ALI scores demonstrated shorter OS and PFS compared to the high ALI group (OS: HR=4.07, p< 0.001; PFS: HR=2.17, p< 0.001). Low ALI was also associated with a lower disease control rate (DCR) (25.0% vs 58.7%, p=0.002), but showed no significant correlation with objective response rate (ORR) (15.6% vs 23.1%, p=0.361). In multivariate analysis incorporating propensity score-matched cohorts (n=62), ALI retained prognostic value for OS (HR=3.74, p=0.001) and PFS (HR=1.84, p=0.049).
Conclusion: Our findings suggest that pretreatment ALI as a promising prognostic biomarker for R/M NPC patients treated with ICIs. Given the exploratory post hoc nature of this analysis, the use of an empirically derived cutoff without external validation and the modest sample size of the matched cohort, these results warrant validation in future prospective studies.
Keywords: ALI, nutrition, ICIs, prognosis
1Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Shenzhen Middle School, Shenzhen, People’s Republic of China; 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, People’s Republic of China; 4West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Meiying Shao, West China School of Public Health and West China Fourth Hospital, Sichuan University, 18#, 3rd Section, Renmin South Road, Chengdu, Sichuan, 610041, People’s Republic of China, Tel +86 028 85508286, Fax +86-28-85423278, Email shaomeiying@scu.edu.cn
Purpose: The Advanced Lung Cancer Inflammation Index (ALI) is a newly introduced index that integrates inflammatory and nutritional statuses to assess malignancies. This study investigates the association between pre-immunotherapy ALI levels and clinical outcomes in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) patients receiving immune checkpoint inhibitors (ICIs) therapy.
Patients and Methods: We conducted an exploratory post hoc analysis of a multicenter, single-arm Phase 2 trial enrolling 153 patients with R/M NPC. This study evaluated the prognostic utility of the pretreatment ALI for overall survival (OS) and progression-free survival (PFS), along with its association with treatment response to ICIs. The optimal ALI cutoff was empirically derived from this cohort. Propensity score matching (PSM) was also applied to assess the independent association between pretreatment ALI and clinical outcomes.
Results: Patients with low ALI scores demonstrated shorter OS and PFS compared to the high ALI group (OS: HR=4.07, p< 0.001; PFS: HR=2.17, p< 0.001). Low ALI was also associated with a lower disease control rate (DCR) (25.0% vs 58.7%, p=0.002), but showed no significant correlation with objective response rate (ORR) (15.6% vs 23.1%, p=0.361). In multivariate analysis incorporating propensity score-matched cohorts (n=62), ALI retained prognostic value for OS (HR=3.74, p=0.001) and PFS (HR=1.84, p=0.049).
Conclusion: Our findings suggest that pretreatment ALI as a promising prognostic biomarker for R/M NPC patients treated with ICIs. Given the exploratory post hoc nature of this analysis, the use of an empirically derived cutoff without external validation and the modest sample size of the matched cohort, these results warrant validation in future prospective studies.
Keywords: ALI, nutrition, ICIs, prognosis